Publication:
SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).

Simple item page
dc.contributor.authorCassinello, J
dc.contributor.authorArranz, J A
dc.contributor.authorPiulats, J M
dc.contributor.authorSanchez, A
dc.contributor.authorPerez-Valderrama, B
dc.contributor.authorMellado, B
dc.contributor.authorCliment, M A
dc.contributor.authorOlmos, D
dc.contributor.authorCarles, J
dc.contributor.authorLazaro, M
dc.date.accessioned2023-01-25T10:01:22Z
dc.date.available2023-01-25T10:01:22Z
dc.date.issued2017-11-13
dc.description.abstractAndrogen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma.
dc.description.versionSi
dc.identifier.citationCassinello J, Arranz JÁ, Piulats JM, Sánchez A, Pérez-Valderrama B, Mellado B, et al. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). Clin Transl Oncol. 2018 Jan;20(1):57-68
dc.identifier.doi10.1007/s12094-017-1783-2
dc.identifier.essn1699-3055
dc.identifier.pmcPMC5785604
dc.identifier.pmid29134562
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785604/pdf
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007/s12094-017-1783-2.pdf
dc.identifier.urihttp://hdl.handle.net/10668/11795
dc.issue.number1
dc.journal.titleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
dc.journal.titleabbreviationClin Transl Oncol
dc.language.isoen
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationHospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number57-68
dc.provenanceRealizada la curación de contenido 19/03/2025
dc.publisherSpringer
dc.pubmedtypeJournal Article
dc.pubmedtypePractice Guideline
dc.relation.publisherversionhttps://dx.doi.org/10.1007/s12094-017-1783-2
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAbiraterone
dc.subjectAndrogen deprivation treatment
dc.subjectCabazitaxel
dc.subjectCastration-resistant prostate cancer
dc.subjectDocetaxel
dc.subjectEnzalutamide
dc.subjectHormone-sensitive advanced prostate cancer
dc.subjectRadium 223
dc.subject.decsDocetaxel
dc.subject.decsNeoplasias de la Próstata
dc.subject.decsCastración
dc.subject.decsPróstata
dc.subject.meshAntineoplastic Agents
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshProstatic Neoplasms
dc.titleSEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number20
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
PMC5785604.pdf
Size:
439.91 KB
Format:
Adobe Portable Document Format
Download
No Thumbnail Available
Name:
Cassinello_SEOMClinical_Correcion.pdf
Size:
688.91 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario Virgen del Rocío
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
SAS - Hospital Regional Universitario de Málaga
SAS - Hospital Universitario Virgen de la Victoria

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía